Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan
Feb. 1, 2013
Roche Holding AG said a next-generation blood cancer drug met its target in the first stage of a trial that could help the treatment replace top-seller Rituxan in patients with chronic lymphocytic leukemia.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing